
Annual report 2025
added 02-10-2026
Medpace Holdings Cash Flow 2011-2026 | MEDP
Annual Cash Flow Medpace Holdings
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
713 M | 609 M | 433 M | 388 M | 263 M | 259 M | 202 M | 157 M | 97.4 M | 91.7 M | - | - | - | - | - |
Depreciation & Amortization |
27.2 M | 27.8 M | 24.1 M | 19 M | 16 M | 11.7 M | 8.36 M | 9.24 M | 8.57 M | 7.44 M | 6.38 M | - | - | - | - |
Accounts Payables |
28.1 M | 32.5 M | 31.9 M | 33.1 M | 25.7 M | 26.6 M | 22.4 M | 16.7 M | 16.7 M | 10.9 M | - | - | - | - | - |
Accounts Receivables |
402 M | 296 M | 298 M | 253 M | 186 M | 161 M | 156 M | 133 M | 83.1 M | 79.8 M | - | - | - | - | - |
All numbers in USD currency
Quarterly Cash Flow Medpace Holdings
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
- | - | 126 M | - | - | - | 153 M | - | - | - | 80.1 M | - | 251 M | - | 46.3 M | - | 192 M | - | 57.3 M | - | 153 M | 93.4 M | 49.1 M | - | 145 M | 80.6 M | 34 M | - | 117 M | 64.6 M | 23.3 M | - | 68.7 M | 29.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Depreciation & Amortization |
6.81 M | 6.78 M | 6.69 M | - | 7.16 M | 6.87 M | 6.63 M | - | 6.33 M | 5.97 M | 5.41 M | - | 4.95 M | 4.71 M | 4.27 M | - | 4.06 M | 3.95 M | 3.81 M | - | 2.99 M | 2.67 M | 2.45 M | - | 2.06 M | 1.98 M | 1.99 M | - | 2.34 M | 2.23 M | 2.31 M | - | 2.24 M | 2.1 M | 2.13 M | - | 1.92 M | 1.79 M | 1.77 M | - | 1.61 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Accounts Payables |
26.5 M | 43.3 M | 61.3 M | 32.5 M | 26.2 M | 27.4 M | 24.4 M | 31.9 M | 29 M | 33.6 M | 37.1 M | 33.1 M | 28.2 M | - | 25.4 M | 25.7 M | 25.1 M | 23.3 M | 21.3 M | 26.6 M | 26.6 M | 26.6 M | 26.6 M | 22.4 M | 22.4 M | 22.4 M | 22.4 M | 16.7 M | 16.7 M | 16.7 M | 16.7 M | 16.7 M | 16.7 M | 16.7 M | 16.7 M | 10.9 M | 10.9 M | 10.9 M | 10.9 M | 8.73 M | 8.73 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Accounts Receivables |
373 M | 378 M | 298 M | 296 M | 311 M | 301 M | 279 M | 298 M | 293 M | 275 M | 258 M | 253 M | 249 M | - | 225 M | 186 M | 186 M | 161 M | 160 M | 161 M | 161 M | 161 M | 161 M | 156 M | 156 M | 156 M | 156 M | 133 M | 133 M | 133 M | 133 M | 83.1 M | 83.1 M | 83.1 M | 83.1 M | 79.8 M | 79.8 M | 79.8 M | 79.8 M | 65.1 M | 65.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Cash Flow Statement is one of the three key financial reports of the company Medpace Holdings, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.
Main Sections of the Cash Flow Statement- Operating Activities
This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash. - Investing Activities
Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign. - Financing Activities
Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.
The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.
Cash flow statements of other stocks in the Diagnostics research sector
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
Anixa Biosciences
ANIX
|
$ 2.81 | -5.39 % | $ 91.2 K | ||
|
Centogene N.V.
CNTG
|
- | -6.23 % | $ 30.6 M | ||
|
Akumin
AKU
|
- | -17.87 % | $ 25.9 M | ||
|
Aspira Women's Health
AWH
|
- | -6.19 % | $ 10.5 M | ||
|
Biocept
BIOC
|
- | -13.05 % | $ 7.29 M | ||
|
Brainsway Ltd.
BWAY
|
$ 23.0 | -1.5 % | $ 99.4 M | ||
|
Burning Rock Biotech Limited
BNR
|
$ 28.5 | -8.06 % | $ 307 M | ||
|
Accelerate Diagnostics
AXDX
|
- | -61.36 % | $ 2.46 M | ||
|
Check-Cap Ltd.
CHEK
|
- | - | $ 9.42 M | ||
|
Co-Diagnostics
CODX
|
- | - | $ 79.8 M | ||
|
BioNano Genomics
BNGO
|
$ 1.13 | -3.26 % | $ 1.44 M | ||
|
Castle Biosciences
CSTL
|
$ 32.44 | 0.22 % | $ 901 M | ||
|
Danaher Corporation
DHR
|
$ 218.83 | -0.41 % | $ 160 B | ||
|
Celcuity
CELC
|
$ 101.7 | -2.37 % | $ 4.01 B | ||
|
Chembio Diagnostics
CEMI
|
- | 0.22 % | $ 16.8 M | ||
|
Quest Diagnostics Incorporated
DGX
|
$ 206.95 | 0.83 % | $ 23 B | ||
|
DexCom
DXCM
|
$ 68.33 | 0.24 % | $ 26.4 B | ||
|
Global Cord Blood Corporation
CO
|
- | - | $ 399 M | ||
|
Enzo Biochem
ENZ
|
- | -8.98 % | $ 14.8 K | ||
|
Genetic Technologies Limited
GENE
|
- | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
- | 0.12 % | $ 80.1 M | ||
|
CareDx, Inc
CDNA
|
$ 19.43 | -5.57 % | $ 1.04 B | ||
|
DermTech
DMTK
|
- | -11.32 % | $ 2.94 M | ||
|
DarioHealth Corp.
DRIO
|
$ 10.4 | -4.76 % | $ 295 M | ||
|
Heska Corporation
HSKA
|
- | - | $ 1.31 B | ||
|
Exact Sciences Corporation
EXAS
|
$ 103.37 | 0.02 % | $ 19.2 B | ||
|
Interpace Biosciences
IDXG
|
$ 1.82 | - | $ 7.98 M | ||
|
Fulgent Genetics
FLGT
|
$ 22.74 | -1.41 % | $ 688 M | ||
|
Lantheus Holdings
LNTH
|
$ 66.24 | -1.39 % | $ 4.58 B | ||
|
Guardant Health
GH
|
$ 104.16 | -0.83 % | $ 12.8 B | ||
|
QIAGEN N.V.
QGEN
|
- | - | $ 10.6 B | ||
|
Mettler-Toledo International
MTD
|
$ 1 400.6 | 0.04 % | $ 28.9 B | ||
|
NeoGenomics
NEO
|
$ 11.36 | -1.26 % | $ 1.44 B | ||
|
HTG Molecular Diagnostics
HTGM
|
- | -20.0 % | $ 1.06 M | ||
|
Natera
NTRA
|
$ 206.93 | -2.23 % | $ 20.4 B | ||
|
Charles River Laboratories International
CRL
|
$ 165.55 | -8.67 % | $ 8.51 B | ||
|
IDEXX Laboratories
IDXX
|
$ 645.07 | -0.23 % | $ 53.2 B | ||
|
Illumina
ILMN
|
$ 117.29 | -1.7 % | $ 18.6 B | ||
|
IQVIA Holdings
IQV
|
$ 177.19 | -2.89 % | $ 32.1 B | ||
|
OPKO Health
OPK
|
$ 1.23 | 0.86 % | $ 854 M | ||
|
Koninklijke Philips N.V.
PHG
|
$ 31.87 | -3.2 % | $ 20 B | ||
|
Biodesix
BDSX
|
$ 10.18 | -2.12 % | $ 1.32 B | ||
|
Laboratory Corporation of America Holdings
LH
|
$ 286.87 | 0.86 % | $ 24.1 B | ||
|
ENDRA Life Sciences
NDRA
|
$ 3.7 | -0.77 % | $ 1.99 M | ||
|
ICON Public Limited Company
ICLR
|
$ 131.48 | -9.05 % | $ 10.8 B | ||
|
Biomerica
BMRA
|
$ 2.23 | -3.88 % | $ 5.12 M |